Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

1.815 -0.075 (-3.97%)
Streaming Delayed Price Updated: 11:34 AM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tiziana Life Sciences Ltd - Common Shares

Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress, Following-Up From Positive Outcomes Data Presented In June
Tiziana (NASDAQ: TLSA) is following up with anticipated human data and announced the acceptance of a late-breaking poster at the 39th Congress of the Europea 
Via Benzinga
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update
--News Direct-- 
Via News Direct
Cathie Wood Sells $25 Million In Tesla Stock As TSLA Flashes Aggressive Buy Signal
Wood's Ark Invest unloaded nearly 100,000 TSLA shares Wednesday. 
Via Investor's Business Daily
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c 
Via Benzinga
Latest AI Quantum Computing News And Company Stock Performances YTD
The global quantum computing market is expected to grow at a CAGR of 38.3% over the next 5 years which presents an incredible opportunity for investors so which AI quantum computing stocks are... 
Via Talk Markets
Topics Artificial Intelligence
Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) has taken a major step towards addressing Secondary Progressive Multiple Sclerosis (SPMS) by initiating Phase 2a clinical trials for its intranasal foralumab... 
Via Benzinga
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Cathie Wood Dumps 170,000 Tesla Shares This Week As TSLA Falls Harder Than The S&P 500
Wood continued selling Tesla shares as TSLA forged a new buy point. 
Via Investor's Business Daily
Topics Stocks
Tesla Cybertruck To Be Used For Oracle's Next-Gen Police Car
Oracle Corp (NYSE: ORCL) co-founder and Executive Chairman Larry Ellison recently made a surprising reveal during his CloudWorld talk. 
Via Benzinga
Tiziana Reveals Alzheimer's Research Milestone With PNAS Journal After FDA IND Green Light
Tiziana Life Sciences Ltd. 
Via Benzinga
Tiziana Life Sciences' Alzheimer's treatment validated in new study
--News Direct-- 
Via News Direct
Tiziana Life Sciences' Alzheimer's treatment validated in new study
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company... 
Via TheNewswire.com
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™... 
Via Benzinga
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervision
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project. 
Via Benzinga
Why Tiziana Life Sciences Stock (TLSA) Is Climbing
Tiziana Life Sciences, Ltd (NASDAQ: TLSA) shares are trading higher Tuesday after the company announced that the FDA has cleared the Investigational New Drug (IND) application for intranasal foralumab... 
Via Benzinga
Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment
--News Direct-- 
Via News Direct
Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after announcing that Tiziana has received FDA clearance... 
Via TheNewswire.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
--News Direct-- 
Via News Direct
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
Tiziana Life Sciences, Inc. 
Via Benzinga
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
--News Direct-- 
Via News Direct
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.